Orchard Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
193
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$478M
Orchard Therapeutics General Information
Description
Developer of hematopoietic stem cell gene therapy designed to transform the lives of patients with rare disorders. The company is focused on autologous ex vivo gene therapy, ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell gene therapy, correcting the underlying cause of a genetic disease permanently using a single administration.
Contact Information
Website
www.orchard-tx.com(Operating Subsidiary)
Corporate Office
- 245 Hammersmith Road
- 3rd Floor
- London W6 8PW
- England, United Kingdom
Corporate Office
- 245 Hammersmith Road
- 3rd Floor
- London W6 8PW
- England, United Kingdom
Orchard Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 24-Jan-2024 | $478M | Completed | Generating Revenue | ||
| 11. PIPE | 10-Mar-2023 | Completed | Generating Revenue | |||
| 10. PIPE | 01-Feb-2021 | Completed | Generating Revenue | |||
| 9. 2PO | 14-Jun-2019 | Completed | Generating Revenue | |||
| 8. General Corporate Purpose | 31-May-2019 | Completed | Clinical Trials - General | |||
| 7. IPO | 31-Oct-2018 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC (Series C) | 13-Aug-2018 | Completed | Clinical Trials - General | |||
| 5. Early Stage VC | 12-Apr-2018 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series B) | 16-Feb-2018 | $119M | $149M | Completed | Clinical Trials - General | |
| 3. Grant | 23-Nov-2016 | $20M | $30.1M | Completed | Startup |
Orchard Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Series C | ||||||||
| Ordinary | ||||||||
| Series B2 | ||||||||
| Series B | 21,198,154 | $0.000013 | $5.24 | $5.24 | 1x | $5.24 | 24.48% | |
| Series A | 21,000,000 | $0.000013 | $1.3 | $1.3 | 1x | $1.3 | 24.25% |
Orchard Therapeutics Comparisons
Industry
Financing
Details
Orchard Therapeutics Competitors (87)
One of Orchard Therapeutics’s 87 competitors is PHAXIAM Therapeutics, a Formerly VC-backed company based in Lyon, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PHAXIAM Therapeutics | Formerly VC-backed | Lyon, France | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| American Gene Technologies | Venture Capital-Backed | Rockville, MD | ||||
| Senti Bio | Formerly VC-backed | South San Francisco, CA |
Orchard Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orchard Therapeutics Patents
Orchard Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4398916-A1 | Compositions and methods for treating or preventing autoimmune diseases | Pending | 08-Sep-2021 | ||
| AU-2022341119-A1 | Compositions and methods for treating or preventing autoimmune diseases | Pending | 08-Sep-2021 | ||
| CA-3231108-A1 | Compositions and methods for treating or preventing autoimmune diseases | Pending | 08-Sep-2021 | ||
| AU-2021324891-A8 | Compositions and methods for treating or preventing hereditary angioedema | Pending | 14-Aug-2020 | ||
| AU-2021324891-A1 | Compositions and methods for treating or preventing hereditary angioedema | Pending | 14-Aug-2020 | C12N15/86 |
Orchard Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orchard Therapeutics Former Investors (35)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 4BIO Capital | Venture Capital | Minority | ||
| Agent Capital | Venture Capital | Minority | ||
| AlbionVC | Venture Capital | Minority | ||
| ArrowMark Partners | Asset Manager | Minority | ||
| Avidity Partners | Asset Manager | Minority |
Orchard Therapeutics Investments (1)
Orchard Therapeutics’s most recent deal was a Corporate Asset Purchase with GlaxoSmithKline (rare disease gene therapy drugs). The deal was made on 12-Apr-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GlaxoSmithKline (rare disease gene therapy drugs) | 12-Apr-2018 | Corporate Asset Purchase | Buildings and Property |
Orchard Therapeutics FAQs
-
When was Orchard Therapeutics founded?
Orchard Therapeutics was founded in 2015.
-
Where is Orchard Therapeutics headquartered?
Orchard Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Orchard Therapeutics?
Orchard Therapeutics has 193 total employees.
-
What industry is Orchard Therapeutics in?
Orchard Therapeutics’s primary industry is Biotechnology.
-
Is Orchard Therapeutics a private or public company?
Orchard Therapeutics is a Private company.
-
What is the current valuation of Orchard Therapeutics?
The current valuation of Orchard Therapeutics is .
-
What is Orchard Therapeutics’s current revenue?
The current revenue for Orchard Therapeutics is .
-
How much funding has Orchard Therapeutics raised over time?
Orchard Therapeutics has raised $836M.
-
Who are Orchard Therapeutics’s investors?
4BIO Capital, Agent Capital, AlbionVC, ArrowMark Partners, and Avidity Partners are 5 of 35 investors who have invested in Orchard Therapeutics.
-
Who are Orchard Therapeutics’s competitors?
PHAXIAM Therapeutics, Kite Pharma, NexImmune, American Gene Technologies, and Senti Bio are some of the 87 competitors of Orchard Therapeutics.
-
When was Orchard Therapeutics acquired?
Orchard Therapeutics was acquired on 24-Jan-2024.
-
Who acquired Orchard Therapeutics?
Orchard Therapeutics was acquired by Kyowa Kirin.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
